Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs Vinflunine in Advanced Urothelial Carcinoma
NCT01830231Phase 3Unknown
- Sponsor
- Associació Per la Recerca Oncològica
- Start
- Oct 2012
- Primary completion
- Nov 2016
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of cabazitaxel ginsenoside liposome injection in transitional cell carcinoma of the urothelium (TCC) (2 arms), sponsored by Associació Per la Recerca Oncològica. Primary endpoints: Objective Response Rate at 18 months and Overall Survival at 18 months. Status: unknown.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT01830231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830231.